Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008;103:1092-1099
Published online before print October 2, 2008, doi: 10.1161/CIRCRESAHA.108.182287
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
103/10/1092    most recent
CIRCRESAHA.108.182287v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Korpisalo, P.
Right arrow Articles by Ylä-Herttuala, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Korpisalo, P.
Right arrow Articles by Ylä-Herttuala, S.
Related Collections
Right arrow Angiogenesis
Right arrow Gene expression
Right arrow Growth factors/cytokines
Right arrow Peripheral vascular disease
Right arrow Doppler ultrasound, Transcranial Doppler etc.
Right arrow Gene therapy
Right arrow Mechanism of atherosclerosis/growth factors
(Circulation Research. 2008;103:1092.)
© 2008 American Heart Association, Inc.


Integrative Physiology

Vascular Endothelial Growth Factor-A and Platelet-Derived Growth Factor-B Combination Gene Therapy Prolongs Angiogenic Effects via Recruitment of Interstitial Mononuclear Cells and Paracrine Effects Rather Than Improved Pericyte Coverage of Angiogenic Vessels

Petra Korpisalo, Henna Karvinen, Tuomas T. Rissanen, Johanna Kilpijoki, Varpu Marjomäki, Peter Baluk, Donald M. McDonald, Yihai Cao, Ulf Eriksson, Kari Alitalo, Seppo Ylä-Herttuala

From the Department of Molecular Medicine (P.K., H.K., T.T.R., J.K., S.Y.-H.), A.I. Virtanen Institute, University of Kuopio, Finland; Department of Biological and Environmental Science (V.M.), Nanoscience Center, University of Jyväskylä, Finland; Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy (P.B., D.M.M.), University of California, San Francisco; Microbiology and Tumor Biology Center Karolinska Institute (Y.C.), Stockholm, Sweden; Ludwig Institute for Cancer Research (U.E.), Stockholm, Sweden; Biomedicum (K.A.), University of Helsinki, Finland; Department of Medicine (S.Y.-H.), University of Kuopio, Finland; and Gene Therapy Unit (S.Y.-H.), Kuopio University, Finland.

Correspondence to Seppo Ylä-Herttuala, MD, PhD, FESC, Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland. E-mail Seppo.Ylaherttuala{at}uku.fi

Vessel stabilization and the inhibition of side effects such as tissue edema are essential in angiogenic gene therapy. Thus, combination gene transfers stimulating both endothelial cell and pericyte proliferation have become of interest. However, there is currently little data to support combination gene transfer in large animal models. In this study, we evaluated the potential advantages of such a strategy by combining the transfer of adenoviral (Ad) vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF)-B into rabbit hindlimb skeletal muscle. AdLacZ alone or in combination with AdVEGF-A were used as controls. Contrast-enhanced ultrasound, modified Miles assay, and immunohistology were used to quantify perfusion, vascular permeability, and capillary size, respectively. Confocal microscopy was used in the assessment of pericyte-coverage. The transfer of AdPDGF-B alone and in combination with AdVEGF-A induced prominent proliferation of {alpha}-smooth muscle actin–, CD31-, RAM11-, HAM56-, and VEGF- positive cells. Although, pericyte recruitment to angiogenic vessels was not improved, combination gene transfer induced a longer-lasting increase in perfusion in both intact and ischemic muscles than AdVEGF-A gene transfer alone. In conclusion, intramuscular delivery of AdVEGF-A and AdPDGF-B, combined, resulted in a prolonged angiogenic response. However, the effects were most likely mediated via paracrine mechanisms rather than an increase in vascular pericyte coverage.


Key Words: angiogenesis • vascular endothelial growth factor • platelet derived growth factor • gene therapy




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
A. Alfranca
VEGF therapy: a timely retreat
Cardiovasc Res, September 1, 2009; 83(4): 611 - 612.
[Full Text] [PDF]


Home page
Circ. Res.Home page
J. Saif, C. Heeschen, and A. Aicher
Add Some Fat to Vascular Progenitor Cell Therapy
Circ. Res., June 19, 2009; 104(12): 1330 - 1332.
[Full Text] [PDF]